Single Nucleotide Variants of the Human TIM-1 IgV Domain with Reduced Ability to Promote Viral Entry into Cells

Viruses. 2022 Sep 26;14(10):2124. doi: 10.3390/v14102124.

Abstract

Human T-cell immunoglobulin mucin 1 (hTIM-1) is known to promote cellular entry of enveloped viruses. Previous studies suggested that the polymorphisms of hTIM-1 affected its function. Here, we analyzed single nucleotide variants (SNVs) of hTIM-1 to determine their ability to promote cellular entry of viruses using pseudotyped vesicular stomatitis Indiana virus (VSIV). We obtained hTIM-1 sequences from a public database (Ensembl genome browser) and identified 35 missense SNVs in 3 loops of the hTIM-1 immunoglobulin variable (IgV) domain, which had been reported to interact with the Ebola virus glycoprotein (GP) and phosphatidylserine (PS) in the viral envelope. HEK293T cells transiently expressing wildtype hTIM-1 or its SNV mutants were infected with VSIVs pseudotyped with filovirus or arenavirus GPs, and their infectivities were compared. Eleven of the thirty-five SNV substitutions reduced the efficiency of hTIM-1-mediated entry of pseudotyped VSIVs. These SNV substitutions were found not only around the PS-binding pocket but also in other regions of the molecule. Taken together, our findings suggest that some SNVs of the hTIM-1 IgV domain have impaired ability to interact with PS and/or viral GPs in the viral envelope, which may affect the hTIM-1 function to promote viral entry into cells.

Keywords: TIM-1; entry; glycoprotein; polymorphism; pseudotyped virus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ebolavirus* / genetics
  • Glycoproteins
  • HEK293 Cells
  • Humans
  • Immunoglobulins
  • Mucin-1
  • Nucleotides
  • Phosphatidylserines
  • Receptors, Virus / genetics
  • Viral Envelope Proteins
  • Virus Internalization*

Substances

  • Mucin-1
  • Receptors, Virus
  • Phosphatidylserines
  • Glycoproteins
  • Immunoglobulins
  • Nucleotides
  • Viral Envelope Proteins

Grants and funding

This research was funded by Grants-in-Aid KAKENHI (21H02734 and 20H03140) from the Japan Society for the Promotion of Science (JSPS), the Science and Technology Research Partnership for Sustainable Development (SATREPS) (JP22jm0110019), the Japan Program for Infectious Diseases Research and Infrastructure (JP21fm0208101 and JP22wm0125008), and Research Program on Emerging and Re-emerging Infectious Diseases (JP22fk0108624) from the Japan Agency for Medical Research and Development (AMED), and the World-leading Innovative and Smart Education (WISE) Program (1801) from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), Japan.